Pain Management · 2021 · 19 citations · 25 references
MedicineNeurologyPharmacotherapyClinical PharmacologyPain MedicineRheumatologyChronic Disease PharmacotherapyClinical TrialsHeadache AssessmentHeadache DisordersHeadache ManagementMigraine PharmacotherapyCalcitonin Gene-related Peptide Monoclonal AntibodiesHumanized Monoclonal AntibodiesMigraine PharmacologyObservational Study EvaluationPreventive Headache TherapyPreventive Migraine TherapyPreventive Migraine TreatmentTreatment Patterns Epidemiology
Fremanezumab is a humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide and is approved in Europe for migraine prevention in adults with ≥4 migraine days/month. The Pan-European Real Life (PEARL) study is a 24-month, prospective, observational study of fremanezumab in chronic or episodic migraine. End points include proportion of patients with ≥50% reduction in monthly migraine days during 6 months of treatment (primary); changes in monthly migraine days, disability scores and acute headache medication use; adherence and persistence; and effectiveness in patients switching from another calcitonin gene-related peptide pathway-targeting monoclonal antibody. PEARL is being conducted in approximately 100 centers in 11 European countries (estimated n = 1100). PEARL will generate important real-world data on effectiveness of fremanezumab and treatment patterns in patients with chronic migraine or episodic migraine.
25
A six-item short-form survey for measuring headache impact: The HIT-6™
Mark Kosinski, Martha Bayliss, John E. Ware et al. · Quality of Life Research · 2003 · 1.3K citations
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein, David W. Dodick, Marcelo E. Bigal et al. · New England Journal of Medicine · 2017 · 803 citations · Full text
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
David W. Dodick, Stephen D. Silberstein, Marcelo E. Bigal et al. · JAMA · 2018 · 573 citations · Full text